Tag Archives: SGLT2 inhibitor

The treatment landscape for type 2 diabetes has changed dramatically over the past decade. While selective SGLT2 inhibitors have become a cornerstone of diabetes management because of their proven cardiovascular and kidney benefits, researchers are now exploring the added potential of dual SGLT1/2 inhibitor therapy for people with diabetes. By …

When a person develops diabetes at a young age, is not overweight, and has several family members with the condition, is it really type 2 diabetes? In many cases, the answer may be no. A growing body of evidence suggests that thousands of people worldwide are living with HNF1A-MODY, a …

For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …